EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Distribution of shares in Verici Dx plc
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that in accordance with the announcement dated 20 June 2022 (the "June 2022 Announcement")1 in relation to the distribution of certain shares it held in Verici Dx plc (the "Verici Dividend Shares"), it is today writing to certain Relevant EKF Shareholders2 who, at the record date for the distribution, held their qualifying interest in EKF via CREST (a Qualifying CREST Account).
The letter sets out instructions as to how such persons may elect to receive all of their Verici Dividend Shares by way of transfer into their Qualifying CREST Account following the expiry of the lock-up period as described in the June 2022 Announcement.
In the event that no request for transfer into a Qualifying CREST Account is made, a Relevant EKF Shareholder will automatically receive their Verici Dividend Shares in certificated form, which may take up to 10 business days from the expiry of the lock-up period.
Notes:
1. https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862
2. A Relevant EKF Shareholder is defined in the June 2022 Announcement as an EKF shareholder who was on the register at the close of business on 24 June 2022, being the record date for the distribution of the Verici Dividend Shares; only those investors who held their EKF interests via CREST at that time are eligible to elect to receive their Verici Dividend Shares into their Qualifying CREST Account.
3. If you are the holder of a Qualifying CREST Account and do not receive any correspondence regarding this matter, please contact LINK as the Company's receiving agent on the number below.
| EKF Diagnostics Holdings plc | |
| Julian Baines, Executive Chair / Marc Davies, CFO | via Walbrook PR |
| | |
| Link Group (Registrars) | By e-mail: shareholderenquiries@linkgroup.co.uk or by telephone: 0371 664 0391
Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales |
|
| |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / George Tzimas / Oliver Platts | |
| | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Lianne Applegarth | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
